I-4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9 Ubumsulwa >98.5% (HPLC) I-Lenvatinib Mesylate Intermediate Factory
I-Ruifu Chemical Supply Lenvatinib Mesylate Intermediates With High Purity
I-Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
I-Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl)-3-Cyclopropylurea CAS 796848-79-8
I-Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
I-Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
I-4-Amino-3-Chlorophenol CAS 17609-80-2
I-4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
I-Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Igama Lekhemikhali | 4-Chloro-7-Methoxyquinoline-6-Carboxamide |
Omqondofana | I-4-Chloro-7-Methoxy-6-Quinolinecarboxamide;I-Lenvatinib Ukungcola 12;I-Lenvatinib Ukungcola B;I-Lenvatinib Ukungcola LFS-B |
Inombolo ye-CAS | 417721-36-9 |
Inombolo yeCAT | I-RF-PI1971 |
Isimo Sesitoko | Esitokweni, Amandla Okukhiqiza 50MT/Ngonyaka |
I-Molecular Formula | I-C11H9ClN2O2 |
Isisindo samangqamuzana | 236.65 |
I-Melting Point | >205℃ (December) |
Ukuminyana | 1.380±0.060 g/cm3 |
Ibhrendi | I-Ruifu Chemical |
Into | Imininingwane |
Ukubukeka | I-Off-White to Light Yellow Powder |
Ukuhlanzeka / Indlela Yokuhlaziya | >98.5% (HPLC) |
Ukulahlekelwa Ekumisweni | <0.50% |
Izinsalela ekushiseni | <0.50% |
Ukungcola Okuphelele | <1.50% |
I-Proton NMR Spectrum | Ivumelana Nesakhiwo |
Izinga Lokuhlola | I-Enterprise Standard |
Ukusetshenziswa | I-Intermediate ye-Lenvatinib Mesylate (CAS: 857890-39-2) |
Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwemfuneko yekhasimende
Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama
I-4-Chloro-7-Methoxyquinoline-6-Carboxamide (CAS: 417721-36-9) isetshenziswa kakhulu njengendawo ephakathi ye-Lenvatinib Mesylate (CAS: 857890-39-2).Ithuthukiswe ngabakwa-Eisai Inc., i-lenvatinib mesylate iyi-vascular endothelial growth factor receptor (VEGF) inhibitor enomsebenzi omelene ne-VEGF subtypes 1, 2, no-3 futhi yagunyazwa yi-FDA ngo-2015 ukuze zelashwe umdlavuza wegilo ohlukile otholakala endaweni. ukuphindaphinda, i-metastatic, noma ukuqhubeka futhi ayizange iphendule ekwelashweni kwe-iodine enemisebe.NgoMeyi 2016, i-FDA yagunyaza umuthi njengendlela yokwelapha eyinhlanganisela ne-everolimus yokwelapha i-advanced renal cell carcinoma.Ngenxa yokuthi i-VEGF (kanye ne-fibroblast growth factor receptors, eyaziwa ngokuthi ama-FGFR) kucatshangwa ukuthi idlala indima emizileni yokubonisa izimpawu zenhliziyo, ukuvimbela i-VEGF2R kanye ne-FGFR kucatshangwa ukuthi yizinqubo ezingemuva komphumela oyinhloko we-lenvatinib mesylate, okuwumfutho wegazi ophezulu.